Clinical Trials Logo

BRAF V600 Mutation clinical trials

View clinical trials related to BRAF V600 Mutation.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04759846 Withdrawn - Metastatic Melanoma Clinical Trials

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Start date: January 21, 2021
Phase: Phase 1
Study type: Interventional

Encorafenib in combination with binimetinib have been approved in USA, Europe, Australia, Japan and Switzerland for the treatment of adult patients with unresectable or metastatic melanoma with BRAF V600 mutation. The main objective of this study is to find a safe and effective dose of encorafenib in combination with binimetinib for patients who have BRAF-mutant metastatic or unresectable melanoma with hepatic dysfunction (i.e. moderate or severe impairment).